Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN E LEWIS

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1871773705
CMS profile
1185195
Location
NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$315.41

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $315.41 13

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $86.96 4
Merck Sharp & Dohme LLC $50.42 1
Gilead Sciences, Inc. $50.25 2
Celgene Corporation $32.17 2
Daiichi Sankyo Inc. $27.86 1
RECORDATI_RARE_DISEASES_INC. $25.52 1
Eisai Inc. $24.77 1
Tempus AI, Inc $17.46 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN E LEWIS

NPI 1871773705 · CMS profile ID 1185195

Allopathic & Osteopathic Physicians / Internal Medicine

NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $315.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $26.8411/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133763064 CMS
Merck Sharp & Dohme LLC $50.4211/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141686325 CMS
Astellas Pharma US Inc $13.9011/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139445248 CMS
Celgene Corporation $15.6911/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101116280 CMS
Celgene Corporation $16.4811/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101116278 CMS
Astellas Pharma US Inc $26.9008/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139347242 CMS
Tempus AI, Inc $17.4606/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150168516 CMS
RECORDATI_RARE_DISEASES_INC. $25.5206/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139164256 CMS
Gilead Sciences, Inc. $23.4105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133763062 CMS
Astellas Pharma US Inc $29.5704/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139354975 CMS
Astellas Pharma US Inc $16.5904/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139324030 CMS
Daiichi Sankyo Inc. $27.8601/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089448692 CMS
Eisai Inc. $24.7701/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110734659 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $66.66 4
PY2020 $66.69 3
PY2021 $99.95 1
PY2022 $20.02 1
PY2023 $169.24 8
PY2024 $315.41 13
PY2025 $261.75 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $333,143.56 79
PY2024 Recipient $1,993.89 3
PY2024 Principal investigator $405,724.59 16
PY2023 Principal investigator $899,284.11 32
PY2022 Principal investigator $114,917.88 36
PY2021 Principal investigator $13,252.00 2
PY2020 Principal investigator $142,805.58 3
PY2019 Principal investigator $60,217.32 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $12,406.40 12/31/2023 Non-covered Recipient Entity
Tulane Cancer Center
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1042499053
Principal investigator 1 Merck Sharp & Dohme LLC $17,325.48 12/31/2023 Non-covered Recipient Entity
Tulane University School of Medicine
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer KEYNOTE-905,EV-303 No dispute reported 06/30/2026 1042510821
Principal investigator 1 Merck Sharp & Dohme LLC $25,594.79 12/31/2023 Non-covered Recipient Entity
Tulane University School of Medicine
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1042535099
Principal investigator 1 Merck Sharp & Dohme LLC $613.60 12/31/2023 Non-covered Recipient Entity
Tulane University School of Medicine
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1042535107
Principal investigator 1 Aveo Pharmaceuticals, Inc. $118.55 10/02/2023 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049072833
Principal investigator 1 Seagen Inc. $820.00 09/20/2023 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995868557
Principal investigator 1 Genentech, Inc. $10,899.55 08/16/2023 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND TULANE CANCER CTR
Phase III study in Adjuvant therapy in Renal Cell Carcinoma patients No dispute reported 06/30/2026 1040221619
Principal investigator 1 Aveo Pharmaceuticals, Inc. $118.55 07/03/2023 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049072813
Principal investigator 1 Aveo Pharmaceuticals, Inc. $118.55 07/03/2023 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049072823
Principal investigator 1 Seagen Inc. $820.00 06/20/2023 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995868543
Principal investigator 1 Janssen Research & Development, LLC $121.00 05/05/2023 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCAT IONAL FUND
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 986154753
Principal investigator 1 Janssen Research & Development, LLC $121.00 05/05/2023 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCAT IONAL FUND
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 986154755
Principal investigator 1 Novartis Pharmaceuticals Corporation $785.87 04/25/2023 Non-covered Recipient Entity
TULANE CANCER CENTER OFFICE OF CLINICAL RESEARCH
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1017194429
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 04/20/2023 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund Dba On Behalfof Tulane University
Research Agreement - Tulane Educational Fund d/b/a Tulane University No dispute reported 06/30/2026 1000195015
Principal investigator 1 Novartis Pharmaceuticals Corporation $128,146.17 04/13/2023 Non-covered Recipient Entity
TULANE CANCER CENTER OFFICE OF CLINICAL RESEARCH
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1017227207
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,557.57 03/08/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049061953
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,961.01 03/08/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062525
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,703.37 03/08/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062887
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,026.00 02/10/2023 Non-covered Recipient Entity
Tulane University
Phase III Adjuvant Bladder (nivo mono) No dispute reported 06/30/2026 1027474997
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,557.57 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049061315
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,557.57 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049061520
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,221.02 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049061709
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,703.37 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049061805
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,557.57 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062375
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,221.02 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062409
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,961.01 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062441
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,557.57 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062599
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,221.02 01/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062673
Principal investigator 1 Novartis Pharmaceuticals Corporation $383,003.88 01/26/2023 Non-covered Recipient Entity
TULANE UNIVERSITY HEALTH SCIENCES CENTER
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1017205059
Principal investigator 1 Seagen Inc. $820.00 01/10/2023 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 995868527
Principal investigator 1 Novartis Pharmaceuticals Corporation $219,980.43 01/09/2023 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1017233027
Principal investigator 1 Novartis Pharmaceuticals Corporation $66,664.62 01/09/2023 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1017234633